Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC

Nadine Abi-Jaoudeh, MD
Published: Saturday, Apr 22, 2017



Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

In a dose-escalating study of the hypoxia-activating agent tirapazamine in combination with transarterial embolization, patients with intermediate-stage HCC were assigned to 1 of 5 cohorts according to dose.

Results showed that the combination was well tolerated. Additionally, there were no dose-limiting toxicities or serious adverse events reported.

The combination is moving toward a phase II study where it will be compared with chemoembolization, says Abi-Jaoudeh.
 


Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

In a dose-escalating study of the hypoxia-activating agent tirapazamine in combination with transarterial embolization, patients with intermediate-stage HCC were assigned to 1 of 5 cohorts according to dose.

Results showed that the combination was well tolerated. Additionally, there were no dose-limiting toxicities or serious adverse events reported.

The combination is moving toward a phase II study where it will be compared with chemoembolization, says Abi-Jaoudeh.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x